Hametner Christian, MacIsaac Rachael L, Kellert Lars, Abdul-Rahim Azmil H, Ringleb Peter A, Lees Kennedy R
From the Department of Neurology, Division of Vascular Neurology, University of Heidelberg, Germany (C.H., L.K., P.A.R.); Queen Elizabeth University Hospital (R.L.M., A.H.A.-R.) and BHF Cardiovascular Research Centre (K.R.L.), Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom; and Department of Neurology, Ludwig-Maximilians-University Munich, Germany (L.K.).
Stroke. 2017 Feb;48(2):367-374. doi: 10.1161/STROKEAHA.116.014323. Epub 2016 Dec 27.
We hypothesized that any sex-related difference in outcome poststroke is explained by other prognostic factors and that the response to intravenous recombinant tissue-type plasminogen activator (r-tPA) is equal in males and females after adjustment for such factors.
We accessed an independent collection of randomized clinical trials-the VISTA (Virtual International Stroke Trials Archive). Data were preprocessed by selecting complete cases (n=8028) and matching females to males (coarsened exact matching, n=4575, 24.3% r-tPA). Outcome was assessed by the 7-point modified Rankin Scale (mRS) measured at 90 days after ischemic stroke. Relationship among variables was estimated by adjusted regression analysis.
In nonthrombolyzed patients, ordinal analysis of mRS adjusting for stroke- and sex-related prognostic factors suggested comparable outcomes for females and males (odds ratio, 0.96; 95% confidence interval, 0.85-1.06). Females responded comparably to r-tPA as did males, irrespective of the outcome definition of mRS (ordinal: P=0.46, relative excess risk because of interaction=0). The number needed to treat was 6.8 and 11.2 for 1 female to achieve mRS score of 0 to 2 and 0 to 1, which was highly congruent with males. Analysis for a nonlinear variation of age-by-sex revealed a good outcome for females <45 years with significant disadvantage thereafter (mRS score of 0-2: P=0.004). No relationship between sex, r-tPA, and bleeding complications was evident.
Functional outcome (mRS) without r-tPA was overall similar between the sexes, as was the response to r-tPA. Nonlinear sex-by-age interaction improved estimates of functional independence; this should be considered in sex-related studies in stroke.
我们假设,卒中后任何与性别相关的结局差异都可由其他预后因素来解释,并且在对这些因素进行调整后,男性和女性对静脉注射重组组织型纤溶酶原激活剂(r-tPA)的反应是相同的。
我们访问了一个独立的随机临床试验集合——VISTA(虚拟国际卒中试验档案库)。通过选择完整病例(n = 8028)并将女性与男性进行匹配(粗精确匹配,n = 4575,24.3%接受r-tPA治疗)对数据进行预处理。结局通过缺血性卒中后90天测量的7分改良Rankin量表(mRS)进行评估。通过调整回归分析估计变量之间的关系。
在未接受溶栓治疗的患者中,对卒中及性别相关预后因素进行调整后的mRS序贯分析表明,女性和男性的结局相当(优势比,0.96;95%置信区间,0.85 - 1.06)。无论mRS的结局定义如何(序贯分析:P = 0.46,交互作用导致的相对超额风险 = 0),女性对r-tPA的反应与男性相当。对于1名女性达到mRS评分为0至2分和0至1分,所需治疗人数分别为6.8和11.2,这与男性高度一致。对年龄与性别的非线性变化分析显示,45岁以下女性结局良好,此后则有明显劣势(mRS评分为0 - 2分:P = 0.004)。性别、r-tPA与出血并发症之间无明显关系。
未接受r-tPA治疗时,两性的功能结局(mRS)总体相似,对r-tPA的反应也是如此。年龄与性别的非线性交互作用改善了对功能独立性的估计;在卒中的性别相关研究中应考虑这一点。